Hayward-based Benitec Biopharma Inc., a promising biotechnology firm at the developmental stage, has made genetic medicines its top priority. With a focus on DNA-directed RNA interference-based therapeutics, the company strives to target chronic and life-threatening human conditions. Among its exciting projects is the development of BB-301, an innovative adeno-associated virus-based gene therapy agent set to assist in treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc., founded in 1995, remains dedicated to changing the course of genetic medicine worldwide.
Benitec Biopharma Inc.'s ticker is BNTC
The company's shares trade on the NASDAQ stock exchange
They are based in Melbourne, Australia
There are 11-50 employees working at Benitec Biopharma Inc.
It is https://benitec.com/
Benitec Biopharma Inc. is in the Healthcare sector
Benitec Biopharma Inc. is in the Biotechnology industry
The following five companies are Benitec Biopharma Inc.'s industry peers: